# A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

> **NCT02521844** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **EDDC (Experimental Drug Development Centre), A*STAR Research Entities** · enrollment: 89 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ETC-1922159
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02521844
- **Lead sponsor:** EDDC (Experimental Drug Development Centre), A*STAR Research Entities
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521844, "A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02521844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*